Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 66
Filtrar
1.
J Am Acad Orthop Surg ; 27(8): e390-e394, 2019 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-30216246

RESUMEN

INTRODUCTION: Postoperative C5 nerve root palsy is a known complication after cervical surgery. The effect of increasing number of levels fused on the prevalence of C5 palsy after anterior cervical diskectomy and fusion (ACDF) is unclear. METHODS: Medical records of ACDF patients that included the C4-5 level at one institution were retrospectively reviewed. C5 palsy was defined as motor decline of the deltoid and/or biceps brachii muscle function by at least 1 level on standard manual muscle testing. RESULTS: A total of 196 patients met the inclusion criteria, with no significant differences noted between groups undergoing single- or multi-level ACDF. The overall C5 palsy rate was 5.1%. Palsy rates were not statistically significant based on the number of levels fused. Six of the 10 patients with C5 palsy had complete recovery of motor strength, whereas 2 patients had at least some level of strength recovery. CONCLUSION: The overall C5 palsy rate was 5.1% for all patients undergoing up to four-level ACDF. The rate of postoperative motor decline was lowest in the patients undergoing two-level ACDF and highest in the single-level group, but this finding did not reach statistical significance. The prognosis for strength recovery by final follow-up is excellent. LEVEL OF EVIDENCE: Level III, Case-control.


Asunto(s)
Vértebras Cervicales/cirugía , Discectomía , Parálisis/enzimología , Complicaciones Posoperatorias/epidemiología , Fusión Vertebral , Estudios de Casos y Controles , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
2.
Glia ; 66(9): 1960-1971, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-29726608

RESUMEN

Myelinating glial cells (MGCs), oligodendrocytes (OLs) in the central nervous system (CNS) and Schwann cells (SCs) in the peripheral nervous system (PNS), generate myelin sheaths that insulate axons. After myelination is completed in adulthood, MGC functions independent from myelin are required to support axon survival, but the underlying mechanisms are still unclear. Dicer is a key enzyme that is responsible for generating functional micro-RNAs (miRNAs). Despite the importance of Dicer in initiating myelination, the role of Dicer in mature MGCs is still unclear. Here, Dicer was specifically deleted in mature MGCs in 2-month old mice (PLP-CreERT; Dicer fl/fl) by tamoxifen administration. Progressive motor dysfunction was observed in the Dicer conditional knockout mice, which displayed hind limb ataxia at 3 months post recombination that deteriorated into paralysis within 5 months. Massive axonal degeneration/atrophy in peripheral nerves was responsible for this phenomenon, but overt demyelination was not observed in either the CNS or PNS. In contrast to the PNS, signs of axonal degeneration were not observed in the CNS of these animals. We induced a Dicer deletion in oligodendroglia at postnatal day 5 in NG2-CreERT; Dicer fl/fl mice to evaluate whether Dicer expression in OLs is essential for axonal survival. Dicer deletion in oligodendroglia did not cause motor dysfunction at the age of 7 months. Neither axonal atrophy nor demyelination was observed in the CNS. Based on our results, Dicer expression in SCs is required to maintain axon integrity in adult PNS, and Dicer is dispensable for maintaining myelin sheaths in MGCs.


Asunto(s)
Axones/enzimología , ARN Helicasas DEAD-box/deficiencia , Vaina de Mielina/enzimología , Degeneración Nerviosa/enzimología , Ribonucleasa III/deficiencia , Animales , Ataxia/enzimología , Ataxia/patología , Atrofia , Axones/patología , ARN Helicasas DEAD-box/genética , Progresión de la Enfermedad , Femenino , Masculino , Ratones Endogámicos C57BL , Ratones Transgénicos , Actividad Motora/fisiología , Vaina de Mielina/patología , Degeneración Nerviosa/patología , Nervio Óptico/enzimología , Nervio Óptico/patología , Parálisis/enzimología , Parálisis/patología , Ribonucleasa III/genética , Nervio Ciático/enzimología , Nervio Ciático/patología , Médula Espinal/enzimología , Médula Espinal/patología , Sustancia Blanca/enzimología , Sustancia Blanca/patología
3.
Pestic Biochem Physiol ; 143: 1-7, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29183576

RESUMEN

Popillia japonica is a generalist herbivore that feeds on >300 host plant species in at least 72 plant families. It is unknown why P. japonica, despite possessing active detoxification enzymes in its gut, is paralyzed when feeding on the petals of one of its preferred host plant, Pelargonium×hortorum, or on artificial diet containing quisqualic acid (QA), the active compound in zonal geranium. We hypothesized that Pelargonium×hortorum or QA do not induce activity of the cytochrome P450, glutathione S transferase (GST), and carboxylesterase (CoE) detoxification enzymes in P. japonica. In this study, P. japonica were fed petals of zonal geranium or agar plugs containing QA, or rose petals, another preferred but non-toxic host. Midgut enzyme activities of P450, GST, and CoE were then assayed after 6, 12, or 24h of feeding. In most cases, P450, GST, and CoE activities were significantly induced in P. japonica midguts by geranium petals and QA, though the induction was slower than with rose petals. Induced enzyme activity reached a peak at 24h after consumption, which coincides with the period of highest recovery from geranium and QA paralysis. This study shows that toxic geranium and QA induce detoxification enzyme activity, but the induced enzymes do not effectively protect P. japonica from paralysis by QA. Further investigation is required through in vitro studies to know if the enzymes induced by geranium are capable of metabolizing QA. This study highlights a rare physiological mismatch between the detoxification tool kit of a generalist and its preferred host.


Asunto(s)
Escarabajos/efectos de los fármacos , Geranium/toxicidad , Ácido Quiscuálico/toxicidad , Animales , Carboxilesterasa/metabolismo , Escarabajos/enzimología , Sistema Enzimático del Citocromo P-450/metabolismo , Citosol/efectos de los fármacos , Citosol/enzimología , Inducción Enzimática/efectos de los fármacos , Flores/toxicidad , Glutatión Transferasa/metabolismo , Inactivación Metabólica , Intestinos/efectos de los fármacos , Intestinos/enzimología , Microsomas/efectos de los fármacos , Microsomas/enzimología , Parálisis/inducido químicamente , Parálisis/enzimología , Rosa/toxicidad
4.
Microb Pathog ; 111: 395-401, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28916318

RESUMEN

Inflammation in Guillain-Barré syndrome (GBS) is manifested by changes in matrix metalloproteinase (MMP) and pro-inflammatory cytokine expression. We investigated the expression of MMP-2, -9 and TNF-α and correlated it with pathological changes in sciatic nerve tissue from Campylobacter jejuni-induced chicken model for GBS. Campylobacter jejuni and placebo were fed to chickens and assessed for disease symptoms. Sciatic nerves were examined by histopathology and immunohistochemistry. Expressions of MMPs and TNF-α, were determined by real-time PCR, and activities of MMPs by zymography. Diarrhea developed in 73.3% chickens after infection and 60.0% of them developed GBS like neuropathy. Pathology in sciatic nerves showed perinodal and/or patchy demyelination, perivascular focal lymphocytic infiltration and myelin swelling on 10th- 20th post infection day (PID). MMP-2, -9 and TNF-α were up-regulated in progressive phase of the disease. Enhanced MMP-2, -9 and TNF-α production in progressive phase correlated with sciatic nerve pathology in C. jejuni-induced GBS chicken model.


Asunto(s)
Infecciones por Campylobacter/enzimología , Campylobacter jejuni/fisiología , Síndrome de Guillain-Barré/enzimología , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Parálisis/enzimología , Animales , Infecciones por Campylobacter/genética , Infecciones por Campylobacter/microbiología , Infecciones por Campylobacter/patología , Campylobacter jejuni/genética , Pollos , Modelos Animales de Enfermedad , Síndrome de Guillain-Barré/genética , Síndrome de Guillain-Barré/microbiología , Síndrome de Guillain-Barré/patología , Humanos , Metaloproteinasa 2 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/genética , Parálisis/genética , Parálisis/microbiología , Nervio Ciático/enzimología , Nervio Ciático/microbiología , Nervio Ciático/patología , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo
5.
J Biol Chem ; 290(47): 28097-28106, 2015 Nov 20.
Artículo en Inglés | MEDLINE | ID: mdl-26400084

RESUMEN

Glutathione peroxidase 4 (GPX4), an antioxidant defense enzyme active in repairing oxidative damage to lipids, is a key inhibitor of ferroptosis, a non-apoptotic form of cell death involving lipid reactive oxygen species. Here we show that GPX4 is essential for motor neuron health and survival in vivo. Conditional ablation of Gpx4 in neurons of adult mice resulted in rapid onset and progression of paralysis and death. Pathological inspection revealed that the paralyzed mice had a dramatic degeneration of motor neurons in the spinal cord but had no overt neuron degeneration in the cerebral cortex. Consistent with the role of GPX4 as a ferroptosis inhibitor, spinal motor neuron degeneration induced by Gpx4 ablation exhibited features of ferroptosis, including no caspase-3 activation, no TUNEL staining, activation of ERKs, and elevated spinal inflammation. Supplementation with vitamin E, another inhibitor of ferroptosis, delayed the onset of paralysis and death induced by Gpx4 ablation. Also, lipid peroxidation and mitochondrial dysfunction appeared to be involved in ferroptosis of motor neurons induced by Gpx4 ablation. Taken together, the dramatic motor neuron degeneration and paralysis induced by Gpx4 ablation suggest that ferroptosis inhibition by GPX4 is essential for motor neuron health and survival in vivo.


Asunto(s)
Muerte Celular , Glutatión Peroxidasa/genética , Neuronas Motoras/patología , Parálisis/enzimología , Animales , Glutatión Peroxidasa/metabolismo , Ratones , Ratones Noqueados , Neuronas Motoras/metabolismo , Fosfolípido Hidroperóxido Glutatión Peroxidasa , Especies Reactivas de Oxígeno/metabolismo , Médula Espinal/metabolismo , Médula Espinal/patología
6.
CNS Neurol Disord Drug Targets ; 13(4): 691-8, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24576002

RESUMEN

Alzheimer's disease (AD) represents a neurological disorder, which is caused by enzymatic degradation of an amyloid precursor protein into short peptide fragments that undergo association to form insoluble plaques. Preliminary studies suggest that cyanobacterial extracts, especially the light-harvesting protein phycocyanin, may provide a means to control the progression of the disease. However, the molecular mechanism of disease control remains elusive. In the present study, intact hexameric phycocyanin was isolated and crystallized from the cyanobacterium Leptolyngbya sp. N62DM, and the structure was solved to a resolution of 2.6 A. Molecular docking studies show that the phycocyanin αß-dimer interacts with the enzyme ß-secretase, which catalyzes the proteolysis of the amyloid precursor protein to form plaques. The molecular docking studies suggest that the interaction between phycocyanin and ß-secretase is energetically more favorable than previously reported inhibitor-ß-secretase interactions. Transgenic Caenorhabditis elegans worms, with a genotype to serve as an AD-model, were significantly protected by phycocyanin. Therefore, the present study provides a novel structure-based molecular mechanism of phycocyanin-mediated therapy against AD.


Asunto(s)
Secretasas de la Proteína Precursora del Amiloide/química , Proteínas Bacterianas/química , Fármacos Neuroprotectores/química , Ficocianina/química , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/enzimología , Animales , Animales Modificados Genéticamente , Proteínas Bacterianas/aislamiento & purificación , Proteínas Bacterianas/farmacología , Caenorhabditis elegans , Cianobacterias , Modelos Animales de Enfermedad , Simulación del Acoplamiento Molecular , Fármacos Neuroprotectores/aislamiento & purificación , Fármacos Neuroprotectores/farmacología , Parálisis/tratamiento farmacológico , Parálisis/enzimología , Ficocianina/aislamiento & purificación , Ficocianina/farmacología , Conformación Proteica , Difracción de Rayos X
7.
J Cell Sci ; 126(Pt 14): 3151-8, 2013 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-23641070

RESUMEN

Triosephosphate isomerase (TPI) is a glycolytic enzyme that converts dihydroxyacetone phosphate (DHAP) into glyceraldehyde 3-phosphate (GAP). Glycolytic enzyme dysfunction leads to metabolic diseases collectively known as glycolytic enzymopathies. Of these enzymopathies, TPI deficiency is unique in the severity of neurological symptoms. The Drosophila sugarkill mutant closely models TPI deficiency and encodes a protein prematurely degraded by the proteasome. This led us to question whether enzyme catalytic activity was crucial to the pathogenesis of TPI sugarkill neurological phenotypes. To study TPI deficiency in vivo we developed a genomic engineering system for the TPI locus that enables the efficient generation of novel TPI genetic variants. Using this system we demonstrate that TPI sugarkill can be genetically complemented by TPI encoding a catalytically inactive enzyme. Furthermore, our results demonstrate a non-metabolic function for TPI, the loss of which contributes significantly to the neurological dysfunction in this animal model.


Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/enzimología , Errores Innatos del Metabolismo de los Carbohidratos/enzimología , Drosophila melanogaster/fisiología , Longevidad , Parálisis/enzimología , Triosa-Fosfato Isomerasa/deficiencia , Triosa-Fosfato Isomerasa/metabolismo , Anemia Hemolítica Congénita no Esferocítica/genética , Animales , Errores Innatos del Metabolismo de los Carbohidratos/genética , Catálisis , Dihidroxiacetona Fosfato/metabolismo , Modelos Animales de Enfermedad , Drosophila melanogaster/enzimología , Femenino , Técnicas de Inactivación de Genes , Prueba de Complementación Genética , Ingeniería Genética , Gliceraldehído 3-Fosfato/metabolismo , Glucólisis/genética , Calor/efectos adversos , Masculino , Mutación/genética , Parálisis/genética , Estrés Fisiológico/genética , Transgenes/genética , Triosa-Fosfato Isomerasa/genética
8.
Neurosci Res ; 71(3): 266-77, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21824499

RESUMEN

c-Jun N-terminal kinase (JNK) mediates neuronal death in response to stress and injury in the CNS and peripheral nervous system. Here, we show that JNK also regulates retrograde axonal degeneration (axonal dieback) after spinal cord injury (SCI) in mice. Activated phospho-JNK was highly expressed in damaged corticospinal tract (CST) axons after thoracic SCI by hemisection. Local administration of SP600125, a JNK inhibitor, prevented accumulation of amyloid-ß precursor protein and retraction of the severed CST axons as well as preserved the axonal arbors rostral to the injury site. The treatment with SP600125 also improved functional recovery of the hindlimbs, assessed by Basso mouse scale open-field scores and the grid-walking test. In Jnk1(-/-) and Jnk3(-/-) mice, we observed prevention of axonal degeneration and enhancement of motor recovery after SCI. These results indicate that both JNK1 and JNK3 induce axonal degeneration and limit motor recovery after SCI. Thus, a JNK inhibitor may be a suitable therapeutic agent for SCI.


Asunto(s)
Proteína Quinasa 10 Activada por Mitógenos/genética , Proteína Quinasa 8 Activada por Mitógenos/fisiología , Recuperación de la Función , Traumatismos de la Médula Espinal/enzimología , Animales , Antracenos/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteína Quinasa 10 Activada por Mitógenos/antagonistas & inhibidores , Proteína Quinasa 10 Activada por Mitógenos/deficiencia , Proteína Quinasa 8 Activada por Mitógenos/antagonistas & inhibidores , Proteína Quinasa 8 Activada por Mitógenos/deficiencia , Regeneración Nerviosa/efectos de los fármacos , Regeneración Nerviosa/genética , Parálisis/enzimología , Parálisis/genética , Parálisis/fisiopatología , Recuperación de la Función/efectos de los fármacos , Recuperación de la Función/genética , Traumatismos de la Médula Espinal/patología , Traumatismos de la Médula Espinal/fisiopatología , Degeneración Walleriana/enzimología , Degeneración Walleriana/patología , Degeneración Walleriana/fisiopatología
9.
Dis Model Mech ; 4(2): 193-202, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21135058

RESUMEN

Axon degeneration is observed in neurodegenerative diseases and neuroinflammatory disorders, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis. The molecular basis of this process remains largely unknown. Here, we show that mice deleted for the tumour suppressor LKB1 (also called STK11) in the spinal cord, some parts of the brain and in the endocrine pancreas (ßLKB1KO mice) develop hind-limb dysfunction and axon degeneration at about 7 weeks. Demyelination and macrophage infiltration are observed in the white matter of these mice, predominantly in the bilateral and anterior funiculi of the thoracic segment of the spinal cord, suggesting damage to the ascending sensory signalling pathway owing to LKB1 deletion in the brain. Microtubule structures were also affected in the degenerated foci, with diminished neurofilament and tubulin expression. Deletion of both PRKAA1 genes, whose products AMPKα1 and AMPKα2 are also downstream targets of LKB1, with the same strategy was without effect. We thus define LKB1 as an intrinsic suppressor of axon degeneration and a possible target for strategies that can reverse this process.


Asunto(s)
Axones/patología , Miembro Posterior/patología , Degeneración Nerviosa/complicaciones , Parálisis/complicaciones , Proteínas Serina-Treonina Quinasas/metabolismo , Proteína Serina-Treonina Quinasa 2 de Interacción con Receptor/metabolismo , Médula Espinal/patología , Proteínas Quinasas Activadas por AMP/metabolismo , Animales , Dominio Catalítico , Movimiento Celular , Eliminación de Gen , Miembro Posterior/fisiopatología , Integrasas/metabolismo , Macrófagos/patología , Ratones , Ratones Noqueados , Microtúbulos/patología , Actividad Motora , Degeneración Nerviosa/fisiopatología , Parálisis/enzimología , Parálisis/fisiopatología , Proteínas Serina-Treonina Quinasas/deficiencia , Células Receptoras Sensoriales/metabolismo , Células Receptoras Sensoriales/patología , Transducción de Señal , Médula Espinal/enzimología , Médula Espinal/fisiopatología , Transgenes/genética
10.
J Toxicol Sci ; 35(6): 795-805, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21139329

RESUMEN

Botulinum neurotoxin serotype A (BoNT/A) inhibits acetylcholine release at the neuromuscular junction in isolated muscles, and ouabain can partially block its effect. However, it is not clear whether ouabain attenuates BoNT/A-induced neuromuscular paralysis in vivo. In this work, we investigated the effects of ouabain on BoNT/A-induced neuromuscular paralysis in mice. Ouabain was administered to mice intraperitoneally immediately after a single injection of BoNT/A into skeletal muscle. The effects of ouabain on BoNT/A-induced muscle paralysis were assessed by quantitative monitoring of muscle tension and digit abduction via the digit abduction scoring (DAS) assay. A single administration of ouabain significantly prolonged BoNT/A-induced neuromuscular paralysis. Moreover, consecutive daily injection of ouabain exacerbated BoNT/A-induced neuromuscular paralysis, and led to a significant decrease in both twitch and tetanic forces as assayed in isolated BoNT/A-injected muscles. We next looked at the effects of ouabain on BoNT/A-induced muscle atrophy. Administration of ouabain led to a decrease in the myofibrillar cross-sectional area (CSAs) by 14 post-BoNT/A injection. In addition, repeated administration of ouabain increased mRNA expression levels of ubiquitin ligases, which are markers of muscle atrophy, in BoNT/A-injected muscle. These results suggest that ouabain exacerbates BoNT/A-induced neuromuscular paralysis via a marked progression of BoNT/A-induced muscle atrophy.


Asunto(s)
Toxinas Botulínicas Tipo A/toxicidad , Músculo Esquelético/efectos de los fármacos , Atrofia Muscular/inducido químicamente , Ouabaína/toxicidad , Parálisis/inducido químicamente , Animales , Sinergismo Farmacológico , Inyecciones Intramusculares , Inyecciones Intraperitoneales , Masculino , Ratones , Ratones Endogámicos , Proteínas Musculares/biosíntesis , Músculo Esquelético/enzimología , Atrofia Muscular/complicaciones , Atrofia Muscular/enzimología , Parálisis/complicaciones , Parálisis/enzimología , ARN/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Proteínas de Motivos Tripartitos , Ubiquitina-Proteína Ligasas/biosíntesis
11.
Hum Mol Genet ; 19(24): 4774-89, 2010 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-20871097

RESUMEN

Mutations in superoxide dismutase 1 (SOD1) are associated with familial cases of amyotrophic lateral sclerosis (fALS). Studies in transgenic mice have suggested that wild-type (WT) SOD1 can modulate the toxicity of mutant SOD1. In the present study, we demonstrate that the effects of WT SOD1 on the age at which transgenic mice expressing mutant human SOD1 (hSOD1) develop paralysis are influenced by the nature of the ALS mutation and the expression levels of WT hSOD1. We show that regardless of whether WT SOD1 changes the course of disease, both WT and mutant hSOD1 accumulate as detergent-insoluble aggregates in symptomatic mice expressing both proteins. However, using a panel of fluorescently tagged variants of SOD1 in a cell model of mutant SOD1 aggregation, we demonstrate that the interactions between mutant and WT SOD1 in aggregate formation are not simply a co-assembly of mutant and WT proteins. Overall, these data demonstrate that the product of the normal SOD1 allele in fALS has potential to influence the toxicity of mutant SOD1 and that complex interactions with the mutant protein may influence the formation of aggregates and inclusion bodies generated by mutant SOD1.


Asunto(s)
Esclerosis Amiotrófica Lateral/enzimología , Esclerosis Amiotrófica Lateral/patología , Proteínas Mutantes/química , Proteínas Mutantes/metabolismo , Superóxido Dismutasa/metabolismo , Envejecimiento/efectos de los fármacos , Esclerosis Amiotrófica Lateral/complicaciones , Animales , Células Cultivadas , Detergentes/farmacología , Cuerpos de Inclusión/efectos de los fármacos , Cuerpos de Inclusión/metabolismo , Ratones , Ratones Transgénicos , Modelos Biológicos , Proteínas Mutantes/genética , Parálisis/complicaciones , Parálisis/enzimología , Parálisis/patología , Unión Proteica/efectos de los fármacos , Estructura Cuaternaria de Proteína , Solubilidad/efectos de los fármacos , Médula Espinal/efectos de los fármacos , Médula Espinal/enzimología , Médula Espinal/patología , Superóxido Dismutasa/genética , Superóxido Dismutasa-1
12.
Proc Natl Acad Sci U S A ; 107(4): 1636-41, 2010 Jan 26.
Artículo en Inglés | MEDLINE | ID: mdl-20080621

RESUMEN

The enzyme ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is one of the most abundant proteins in the mammalian nervous system. In humans, UCH-L1 is also found in the ubiquitinated inclusion bodies that characterize neurodegenerative diseases in the brain, suggesting its involvement in neurodegeneration. The physiologic role of UCH-L1 in neurons, however, remains to be further elucidated. For example, previous studies have provided evidence both for and against the role of UCH-L1 in synaptic function in the brain. Here, we have characterized a line of knockout mice deficient in the UCH-L1 gene. We found that, in the absence of UCH-L1, synaptic transmission at the neuromuscular junctions (NMJs) is markedly impaired. Both spontaneous and evoked synaptic activity are reduced; paired pulse-facilitation is impaired, and synaptic transmission fails to respond to high-frequency, repetitive stimulation at the NMJs of UCH-L1 knockout mice. Morphologic analyses of the NMJs further revealed profound structural defects-loss of synaptic vesicles and accumulation of tubulovesicular structures at the presynaptic nerve terminals, and denervation of the muscles in UCH-L1 knockout mice. These findings demonstrate that UCH-L1 is required for the maintenance of the structure and function of the NMJ and that the loss of normal UCH-L1 activity may result in neurodegeneration in the peripheral nervous system.


Asunto(s)
Unión Neuromuscular/citología , Unión Neuromuscular/enzimología , Ubiquitina Tiolesterasa/metabolismo , Animales , Progresión de la Enfermedad , Ratones , Ratones Noqueados , Microscopía Electrónica de Transmisión , Mutación , Parálisis/enzimología , Parálisis/genética , Parálisis/patología , Transmisión Sináptica , Ubiquitina Tiolesterasa/deficiencia , Ubiquitina Tiolesterasa/genética
13.
Neurol Res ; 30(7): 761-7, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18593519

RESUMEN

OBJECTIVE: The complement system and activated neutrophils are thought to play a major role in initiating some of the inflammatory events that occur in spinal cord injury. The aim of the present study was to assess the effects of C1 esterase inhibitor (C1-INH) on traumatic spinal cord injury (SCI) in the rat. METHODS: Thirty-eight male Wistar rats were used. Just after SCI by a pneumatic impact device, C1-INH (n=16, C1-INH group) or saline (n=16, saline group) was administered. Sham operated animals (n=6, sham group) received only laminectomy. Eighteen (six from each group) rats were killed and an assessment of leukocyte infiltration by myeloperoxidase (MPO) activity and immunoreactivity of MPO were performed 24 hours after SCI. Twenty (ten from each of C1-INH and saline groups) rats were examined using behavioral function on post-operative days. They were also examined after 7 days by histologic analysis using Luxol fast blue for axons and myelin. Lesion volume was calculated by considering a lesion as being composed of two cones with juxtaposed bases. During the experiment, sequential changes in regional spinal cord blood flow (rSCBF) were measured using the laser Doppler (LD) scanning technique. RESULTS: The recovery of motor function was better in the C1-INH group than in the saline group. In the C1-INH group, immunoreactivity of MPO showed a tendency to be smaller than that of the saline group. Lesion volume was significantly smaller in the C1-INH group than in the control group (p<0.01) and MPO activity was also significantly smaller in the C1-INH group than in the control group (p<0.01). After SCI, the rSCBF value decreased gradually and significantly in both injured groups. Significant differences were observed from 30 to 120 minutes after SCI (p<0.05). DISCUSSION: The results of this study provided the first evidence that C1-INH reduced accumulation of polymorphonuclear leukocytes (PMLs) and neuronal damage in acute stage after SCI. This protection was not related to an improvement in rSCBF.


Asunto(s)
Proteína Inhibidora del Complemento C1/farmacología , Complemento C1s/antagonistas & inhibidores , Fármacos Neuroprotectores/farmacología , Traumatismos de la Médula Espinal/tratamiento farmacológico , Traumatismos de la Médula Espinal/enzimología , Médula Espinal/efectos de los fármacos , Animales , Quimiotaxis de Leucocito/efectos de los fármacos , Quimiotaxis de Leucocito/inmunología , Proteína Inhibidora del Complemento C1/uso terapéutico , Complemento C1s/metabolismo , Proteínas del Sistema Complemento/inmunología , Proteínas del Sistema Complemento/metabolismo , Modelos Animales de Enfermedad , Inmunohistoquímica , Masculino , Degeneración Nerviosa/tratamiento farmacológico , Degeneración Nerviosa/enzimología , Degeneración Nerviosa/fisiopatología , Fármacos Neuroprotectores/uso terapéutico , Neutrófilos/efectos de los fármacos , Neutrófilos/enzimología , Parálisis/tratamiento farmacológico , Parálisis/enzimología , Parálisis/fisiopatología , Peroxidasa/análisis , Peroxidasa/inmunología , Peroxidasa/metabolismo , Ratas , Ratas Wistar , Recuperación de la Función/efectos de los fármacos , Recuperación de la Función/fisiología , Flujo Sanguíneo Regional/efectos de los fármacos , Flujo Sanguíneo Regional/fisiología , Médula Espinal/irrigación sanguínea , Médula Espinal/fisiopatología , Traumatismos de la Médula Espinal/fisiopatología , Resultado del Tratamiento
14.
J Biol Chem ; 283(27): 18883-91, 2008 Jul 04.
Artículo en Inglés | MEDLINE | ID: mdl-18434312

RESUMEN

The seven antigenically distinct serotypes of Clostridium botulinum neurotoxins cleave specific soluble N-ethylmaleimide-sensitive factor attachment protein receptor complex proteins and block the release of neurotransmitters that cause flaccid paralysis and are considered potential bioweapons. Botulinum neurotoxin type A is the most potent among the clostridial neurotoxins, and to date there is no post-exposure therapeutic intervention available. To develop inhibitors leading to drug design, it is imperative that critical interactions between the enzyme and the substrate near the active site are known. Although enzyme-substrate interactions at exosites away from the active site are mapped in detail for botulinum neurotoxin type A, information about the active site interactions is lacking. Here, we present the crystal structures of botulinum neurotoxin type A catalytic domain in complex with four inhibitory substrate analog tetrapeptides, viz. RRGC, RRGL, RRGI, and RRGM at resolutions of 1.6-1.8 A. These structures show for the first time the interactions between the substrate and enzyme at the active site and delineate residues important for substrate stabilization and catalytic activity. We show that OH of Tyr(366) and NH(2) of Arg(363) are hydrogen-bonded to carbonyl oxygens of P1 and P1' of the substrate analog and position it for catalytic activity. Most importantly, the nucleophilic water is replaced by the amino group of the N-terminal residue of the tetrapeptide. Furthermore, the S1' site is formed by Phe(194), Thr(215), Thr(220), Asp(370), and Arg(363). The K(i) of the best inhibitory tetrapeptide is 157 nm.


Asunto(s)
Armas Biológicas , Toxinas Botulínicas Tipo A/antagonistas & inhibidores , Toxinas Botulínicas Tipo A/química , Clostridium botulinum/enzimología , Inhibidores Enzimáticos/química , Oligopéptidos/química , Sitios de Unión , Toxinas Botulínicas Tipo A/toxicidad , Cristalografía por Rayos X , Inhibidores Enzimáticos/uso terapéutico , Oligopéptidos/uso terapéutico , Parálisis/inducido químicamente , Parálisis/tratamiento farmacológico , Parálisis/enzimología , Estructura Terciaria de Proteína/fisiología , Relación Estructura-Actividad
15.
J Biol Chem ; 283(9): 5908-17, 2008 Feb 29.
Artículo en Inglés | MEDLINE | ID: mdl-18086666

RESUMEN

Neuropathy target esterase (NTE) is a member of the family of patatin domain-containing proteins and exhibits phospholipase activity in brain and cultured cells. NTE was originally identified as target enzyme for organophosphorus compounds that cause a delayed paralyzing syndrome with degeneration of nerve axons. Here we show that the structurally related murine protein NTE-related esterase (NRE) is a potent lysophospholipase. The enzyme efficiently hydrolyzes sn-1 esters in lysophosphatidylcholine and lysophosphatidic acid. No lipase activity was observed when triacylglycerols, cholesteryl esters, retinyl esters, phosphatidylcholine, or monoacylglycerol were used as substrates. Although NTE is predominantly expressed in the nervous system, we found the highest NRE mRNA levels in testes, skeletal muscle, cardiac muscle, and adipose tissue. Induction of NRE mRNA concentrations in these tissues during fasting suggested a nutritional regulation of enzyme expression and, in accordance with this observation, insulin reduced NRE mRNA levels in a dose-dependent manner in 3T3-L1 adipocytes. A green fluorescent protein-NRE fusion protein colocalized to the endoplasmic reticulum and lipid droplets. Thus, NRE is a previously unrecognized ER- and lipid droplet-associated lysophospholipase. Regulation of enzyme expression by the nutritional status and insulin suggests a role of NRE in the catabolism of lipid precursors and/or mediators that affect energy metabolism in mammals.


Asunto(s)
Hidrolasas de Éster Carboxílico/metabolismo , Regulación Enzimológica de la Expresión Génica/fisiología , Hipoglucemiantes/farmacología , Insulina/farmacología , Metabolismo de los Lípidos/fisiología , Lisofosfolipasa/biosíntesis , Células 3T3-L1 , Animales , Axones/enzimología , Encéfalo/enzimología , Hidrolasas de Éster Carboxílico/genética , Relación Dosis-Respuesta a Droga , Retículo Endoplásmico/enzimología , Retículo Endoplásmico/genética , Ayuno/fisiología , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Metabolismo de los Lípidos/efectos de los fármacos , Lisofosfatidilcolinas/genética , Lisofosfatidilcolinas/metabolismo , Lisofosfolipasa/genética , Lisofosfolípidos/genética , Lisofosfolípidos/metabolismo , Masculino , Ratones , Especificidad de Órganos/fisiología , Parálisis/enzimología , Parálisis/genética , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Especificidad por Sustrato/fisiología , Síndrome
16.
Proc Natl Acad Sci U S A ; 103(41): 14987-93, 2006 Oct 10.
Artículo en Inglés | MEDLINE | ID: mdl-17008404

RESUMEN

To identify genes required for maintaining neuronal viability, we screened our collection of Drosophila temperature-sensitive paralytic mutants for those exhibiting shortened lifespan and neurodegeneration. Here, we describe the characterization of wasted away (wstd), a recessive, hypomorphic mutation that causes progressive motor impairment, vacuolar neuropathology, and severely reduced lifespan. We demonstrate that the affected gene encodes the glycolytic enzyme, triosephosphate isomerase (Tpi). Mutations causing Tpi deficiency in humans are also characterized by progressive neurological dysfunction, neurodegeneration, and early death. In Tpi-deficient flies and humans, a decrease in ATP levels did not appear to cause the observed phenotypes because ATP levels remained normal. We also found no genetic evidence that the mutant Drosophila Tpi was misfolded or involved in aberrant protein-protein associations. Instead, we favor the hypothesis that mutations in Tpi lead to an accumulation of methylglyoxal and the consequent enhanced production of advanced glycation end products, which are ultimately responsible for the death and dysfunction of Tpi-deficient neurons. Our results highlight an essential protective role of Tpi and support the idea that advanced glycation end products may also contribute to pathogenesis of other neurological disorders.


Asunto(s)
Proteínas de Drosophila/genética , Drosophila melanogaster/genética , Trastornos Heredodegenerativos del Sistema Nervioso/genética , Trastornos Heredodegenerativos del Sistema Nervioso/mortalidad , Mutagénesis , Parálisis/genética , Parálisis/mortalidad , Triosa-Fosfato Isomerasa/genética , Animales , Modelos Animales de Enfermedad , Proteínas de Drosophila/deficiencia , Drosophila melanogaster/enzimología , Femenino , Productos Finales de Glicación Avanzada/biosíntesis , Trastornos Heredodegenerativos del Sistema Nervioso/enzimología , Trastornos Heredodegenerativos del Sistema Nervioso/patología , Humanos , Masculino , Parálisis/enzimología , Parálisis/patología , Piruvaldehído/metabolismo , Triosa-Fosfato Isomerasa/deficiencia , Triosa-Fosfato Isomerasa/metabolismo
17.
Brain Res ; 1035(2): 206-10, 2005 Feb 28.
Artículo en Inglés | MEDLINE | ID: mdl-15722060

RESUMEN

This study examined whether phenidone, a dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), affects the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in the rat, and the expression of both COX-1/-2 and 5-LOX in EAE spinal cords. Oral phenidone (200 mg/kg) significantly suppressed the incidence and clinical severity of EAE paralysis. Western blot analysis showed that phenidone significantly inhibited the increases in COX-1/-2 and 5-LOX in the spinal cords of rats with EAE. This finding was paralleled by immunohistochemical observations. Overall, these findings suggest that COX-1/-2 and 5-LOX are important inflammatory mediators in the pathogenesis of EAE, and that the inhibition of both COX and LOX ameliorates the autoimmune disorder of the central nervous system.


Asunto(s)
Inhibidores de la Ciclooxigenasa/uso terapéutico , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Encefalomielitis Autoinmune Experimental/enzimología , Inhibidores de la Lipooxigenasa/uso terapéutico , Parálisis/tratamiento farmacológico , Parálisis/enzimología , Pirazoles/uso terapéutico , Animales , Araquidonato 5-Lipooxigenasa/biosíntesis , Ciclooxigenasa 1 , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Masculino , Proteínas de la Membrana , Prostaglandina-Endoperóxido Sintasas/biosíntesis , Ratas , Ratas Endogámicas Lew
18.
Neurotoxicology ; 24(1): 43-53, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12564381

RESUMEN

Muscle injury and its role in the development of Type II paralysis was studied in 25 patients with acute organophosphate poisoning. All patients were assessed for severity of poisoning at admission and through the course of poisoning for the development and duration of intermediate syndrome (IS) (Type II paralysis). Blood levels of acetylcholinesterase, creatine kinase, creatine kinase MM, LDH and LDH5 were estimated through the course of the poisoning. Of the 25 patients, 22 were severely poisoned and 3 had mild to moderate poisoning. Severely poisoned patients had a significantly greater rate of developing intermediate syndrome (17/22) (P = 0.026). Type I paralysis and fasciculations occurred in 76 and 70.5% of patients who developed intermediate syndrome, in comparison to 38 and 50%, respectively, of those who did not develop intermediate syndrome. Weakness developed in the same groups of muscles in both Types I and II paralysis but was of longer duration in patients who developed Type II paralysis. Acetylcholinesterase was inhibited > 90% throughout the course of poisoning with greater inhibition in patients with longer duration intermediate syndrome. Muscle injury was seen in all patients beginning at admission, peaking over the first 5 days and then declining over the next 5 days. Temporal profiles of blood muscle isoenzymes showed significantly greater muscle injury in those patients with greater severity of poisoning at admission, those who developed intermediate syndrome and in patients with longer duration intermediate syndrome. The findings of this study suggest that Types I and II paralysis in organophosphate poisoning are not separate syndromes but a clinical continuum determined by the severity of poisoning. The magnitude of organophosphate exposure and of muscle injury during the cholinergic crises appears to determine the occurrence and severity of intermediate syndrome.


Asunto(s)
Músculo Esquelético/efectos de los fármacos , Intoxicación por Organofosfatos , Parálisis/inducido químicamente , Acetilcolinesterasa/metabolismo , Adulto , Humanos , Debilidad Muscular/inducido químicamente , Debilidad Muscular/enzimología , Debilidad Muscular/patología , Músculo Esquelético/enzimología , Músculo Esquelético/lesiones , Músculo Esquelético/patología , Parálisis/enzimología , Parálisis/patología , Estudios Prospectivos , Análisis de Regresión , Estadísticas no Paramétricas
19.
J Virol ; 76(16): 8335-46, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12134038

RESUMEN

We previously characterized the expression and function of the protein tyrosine phosphatase SHP-1 in the glia of the central nervous system (CNS). In the present study, we describe the role of SHP-1 in virus infection of glia and virus-induced demyelination in the CNS. For in vivo studies, SHP-1-deficient mice and their normal littermates received an intracerebral inoculation of an attenuated strain of Theiler's murine encephalomyelitis virus (TMEV). At various times after infection, virus replication, TMEV antigen expression, and demyelination were monitored. It was found that the CNS of SHP-1-deficient mice uniquely displayed demyelination and contained substantially higher levels of virus than did that of normal littermate mice. Many infected astrocytes and oligodendrocytes were detected in both brains and spinal cords of SHP-1-deficient but not normal littermate mice, showing that the virus replicated and spread at a much higher rate in the glia of SHP-1-deficient animals. To ascertain whether the lack of SHP-1 in the glia was primarily responsible for these differences, glial samples from these mice were cultured in vitro and infected with TMEV. As in vivo, infected astrocytes and oligodendrocytes of SHP-1-deficient mice were much more numerous and produced more virus than did those of normal littermate mice. These findings indicate that SHP-1 is a critical factor in controlling virus replication in the CNS glia and virus-induced demyelination.


Asunto(s)
Infecciones por Cardiovirus/etiología , Infecciones del Sistema Nervioso Central/etiología , Enfermedades Desmielinizantes/etiología , Proteínas Tirosina Fosfatasas/metabolismo , Theilovirus/patogenicidad , Animales , Astrocitos/enzimología , Astrocitos/virología , Encéfalo/patología , Encéfalo/virología , Infecciones por Cardiovirus/enzimología , Infecciones por Cardiovirus/patología , Infecciones por Cardiovirus/virología , Infecciones del Sistema Nervioso Central/enzimología , Infecciones del Sistema Nervioso Central/patología , Infecciones del Sistema Nervioso Central/virología , Enfermedades Desmielinizantes/enzimología , Enfermedades Desmielinizantes/patología , Enfermedades Desmielinizantes/virología , Péptidos y Proteínas de Señalización Intracelular , Ratones , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Mutantes , Neuroglía/enzimología , Neuroglía/virología , Oligodendroglía/enzimología , Oligodendroglía/virología , Parálisis/enzimología , Parálisis/etiología , Parálisis/virología , Proteína Tirosina Fosfatasa no Receptora Tipo 6 , Proteínas Tirosina Fosfatasas/deficiencia , Proteínas Tirosina Fosfatasas/genética , Médula Espinal/patología , Médula Espinal/virología , Theilovirus/fisiología , Replicación Viral/fisiología
20.
Neuroreport ; 13(2): 243-7, 2002 Feb 11.
Artículo en Inglés | MEDLINE | ID: mdl-11893918

RESUMEN

Cyclin-dependent kinase 5 (Cdk5) was originally identified as a serine/threonine kinase and subsequently demonstrated to play a critical role in the development of CNS. We recently reported the novel function of Cdk5 in the neuregulin signaling pathway during the development of neuromuscular junction (NMJ). Here, we report the regulation of Cdk5 and p35 in rat skeletal muscle after nerve injury. Northern blot analysis revealed that Cdk5 and p35 transcripts were up-regulated in muscle after nerve denervation. The temporal profiles for the regulation of Cdk5 and p35 transcripts were different, suggesting that these changes in gene transcription might be regulated by different mechanism. Our finding on the ability of tetrodotoxin to induce p35 transcript in muscle suggested that electrical activity could regulate p35 expression. In addition to the induction of mRNA expression, the total Cdk5 and p35-associated kinase activity in muscle increased prominently after nerve denervation. Taken together, our findings suggest that Cdk5 and p35 may play important physiological roles in muscle regeneration following nerve injury.


Asunto(s)
Quinasas Ciclina-Dependientes/metabolismo , Desnervación , Músculo Esquelético/enzimología , Músculo Esquelético/inervación , Parálisis/enzimología , Nervio Ciático , Animales , Quinasa 5 Dependiente de la Ciclina , Quinasas Ciclina-Dependientes/genética , Proteínas del Tejido Nervioso/genética , Unión Neuromuscular/enzimología , Parálisis/inducido químicamente , Parálisis/metabolismo , ARN Mensajero/metabolismo , Ratas , Nervio Ciático/efectos de los fármacos , Tetrodotoxina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA